Vor Biopharma, Inc. (VOR)

Over the past six months, Vor Biopharma's stock price has declined by approximately 61.23%, with a 52-week trading range between $2.62 and $65.80. Key events include a $150 million private placement in December 2025, a $100 million public offering of common stock in November 2025, the Third Quarter 2025 Financial Results report and corporate update in November 2025, participation in the 44th Annual J.P. Morgan Healthcare Conference and the 46th Annual TD Cowen Health Care Conference in January and February 2026, respectively, and the appointment of Andrew Levin and Wouter Joustra to its Board of Directors in December 2025.

Vor Biopharma's products and services do not exhibit typical consumer-driven demand seasonality. The demand for such investigational therapies is primarily driven by factors such as disease prevalence, ongoing clinical trial progress, regulatory approvals, and eventual physician and patient adoption, rather than seasonal fluctuations. The company's revenue is currently reported as $0.00 USD, indicating it is still in the development phase for most of its products.

Vor Biopharma, Inc. is a clinical-stage biotechnology company focused on developing cell and genome engineering therapies for cancer and autoimmune diseases. The company's core business revolves around re-engineering a patient's own blood-forming stem cells and developing targeted therapies. For hematological malignancies, the company is advancing several investigational therapies, including tremtelectogene empogeditemcel (trem-cel) for acute myeloid leukemia (AML) and other blood cancers, VCAR33, VBP101, VADC45, VOR333, VUC-566, and VUC-722. Vor Biopharma has also focused on transforming the treatment of autoimmune diseases with telitacicept, a novel dual-target fusion protein designed to inhibit BLyS (BAFF) and APRIL. Telitacicept has received approval in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG).

Vor Biopharma's corporate office is located in Boston, Massachusetts, United States. While its headquarters are in the U.S., the company has a global outlook for its product development and commercialization. Telitacicept has achieved commercial approvals in China, and Vor Biopharma is pursuing a global Phase 3 clinical trial for telitacicept in generalized myasthenia gravis across the United States, Europe, and South America.

Vor Biopharma's reputation has been influenced by its clinical progress and strategic financial activities. Analyst ratings show a generally positive sentiment, with 83% recommending a "Buy" and 16.7% a "Hold" for the stock. Key events impacting its reputation include positive Phase 3 study results of telitacicept meeting its primary endpoint in August 2025, positive 48-week results from a Phase 3 study of telitacicept in primary Sjögren's disease in China in October 2025, the publication of positive Phase 3 trial results for telitacicept in systemic lupus erythematosus in China in the New England Journal of Medicine in November 2025, positive Phase 3 results for telitacicept in adults with IgA nephropathy (IgAN) in China in November 2025, an analyst initiating a "Hold" rating on the durable telitacicept MG study data in December 2025, and an analyst report expressing concerns about the company being "Short On Cash, Too Much Uncertainty For Now" in February 2026.

Vor Biopharma Inc. has a diverse ownership structure with 67 institutional owners and shareholders. Major institutional owners include Ra Capital Management, L.p., Fcpm Iii Services B.v., Frazier Life Sciences Management, L.P., Fmr Llc, VR Adviser, LLC, Paradigm Biocapital Advisors LP, Great Point Partners Llc, NEXTBio Capital Management LP, Susquehanna International Group, Llp and Caligan Partners LP. Institutions hold approximately 38.5% of the shares, VC/PE firms hold about 27.9%, the general public holds 30.8%, and individual insiders hold 2.85%.